Skip to content

DIFFERENT SARS-COV-2 VARIANTS' EFFECT ON THE COURSE OF COVID-19 IN ESTONIAN CHILDREN

DIFFERENT SARS-COV-2 VARIANTS' EFFECT ON THE COURSE OF COVID-19 IN ESTONIAN CHILDREN

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06784713
Enrollment
127277
Registered
2025-01-20
Start date
2020-02-27
Completion date
2023-10-23
Last updated
2025-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID - 19, Diabetes Mellitus, MIS-C Associated With COVID-19, Post-COVID Conditions

Brief summary

The study focuses on Estonian children under 18 who had COVID-19 from 27.02.2020 to 01.03.2023. The main aim is to find out the risk factors for severe COVID-19 in children. In order to do that the study includes their demographic data, vaccination status, and details about the severity of illness, such as hospitalization and long-term effects of COVID-19.

Detailed description

Data is collected for all children under 18 years old in Estonia who were diagnosed with COVID-19 between 27.02.2020 and 01.03.2024 (either with the ICD-10 codes U07.1/U07.2 and/or a positive SARS-CoV-2 test. The following data is collected for each patient: age at the time of COVID-19 diagnosis, gender, place of residence, and COVID-19 vaccination status. In order to assess the severity of the disease, the following data is collected for each case: hospitalization due to COVID-19, length of hospitalization, need for intensive care, need for mechanical ventilation, fatal outcomes, and occurrence of long-term sequelae (post-COVID-19 condition and pediatric systemic inflammatory response syndrome). Additionally, data on any comorbid chronic and acute diseases of the children in the study group is collected. The outcome measures are compared across five different SARS-CoV-2 VOC periods: original, Alpha, Delta, Omicron BA.1/BA.2 and Omicron BA.4/BA.5.

Interventions

None listed

Sponsors

University of Tartu
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
0 Days to 18 Years
Healthy volunteers
No

Inclusion criteria

* SARS-CoV-2 positivity or COVID-19 diagnosis (ICD-10 codes U07.1, U07.2) * COVID-19 diagnosis in the following time period: 27/Feb/2020 to 01/Mar/2023

Exclusion criteria

* age above 18 years

Design outcomes

Primary

MeasureTime frameDescription
Hospitalization due to COVID-19From enrollment to the end of the observation period in Oct 2023Cases requiring hospital care due to COVID-19, hospitalization length, need for intensive care
Post-COVID conditionFrom enrollment to the end of the observation period in Oct 2023Receiving post COVID-19 syndrome (ICD-10 code U09) diagnosis after acute COVID-19 infection, the time from COVID-19 to long-COVID
Diabetes mellitusFrom enrollment to the end of the observation period in Oct 2023Receiving diabetes mellitus (ICD-10 code E10) diagnosis after acute COVID-19 infection
MIS-CFrom enrollment to the end of the observation period in Oct 2023Receiving MIS-C diagnosis (ICD-10 code U10)
MortalityFrom enrollment to the end of the observation period in Oct 2023Cases of COVID-19 that resulted in death

Countries

Estonia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026